Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
about
Predictive biomarkers in precision medicine and drug development against lung cancerRisk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.Analysis of aqueous humor concentrations of cytokines in retinoblastoma.EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cellsEGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibodyA fusion cytokine coupling GMCSF to IL9 induces heterologous receptor clustering and STAT1 hyperactivation through JAK2 promiscuity.A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.Oncogene addiction in gliomas: implications for molecular targeted therapyCell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo.Shikonin causes cell-cycle arrest and induces apoptosis by regulating the EGFR-NF-κB signalling pathway in human epidermoid carcinoma A431 cells.Nuclear PKM2 regulates β-catenin transactivation upon EGFR activationProtein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α.PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesisEGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancerMIIP accelerates epidermal growth factor receptor protein turnover and attenuates proliferation in non-small cell lung cancer.Epidermal growth factor receptor targeting and challenges in glioblastoma.Epidermal growth factor (EGF) receptor-ligand based molecular staging predicts prognosis in head and neck squamous cell carcinoma partly due to deregulated EGF- induced amphiregulin expression.EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180.Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.Neuro-oncologic applications of exosomes, microvesicles, and other nano-sized extracellular particles.Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.Viruses exploit the function of epidermal growth factor receptor.Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials.Epidermal growth factor receptor is overexpressed in neuroblastoma tissues and cells.Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.Cancer systems biology: signal processing for cancer research.Molecular targeted agents--where we are and where we are going.RNF8 mediates histone H3 ubiquitylation and promotes glycolysis and tumorigenesis.Phytosphingosine exhibits an anti-epithelial-mesenchymal transition function by the inhibition of EGFR signaling in human breast cancer cells.Screening of novel RGD peptides to modify nanoparticles for targeted cancer therapy.[Expressions of c-Cbl, Cbl-b and EGFR and its role of prognosis in NSCLC].ROS-Mediated Mitochondrial Pathway is Required for Manilkara Zapota (L.) P. Royen Leaf Methanol Extract Inducing Apoptosis in the Modulation of Caspase Activation and EGFR/NF-κB Activities of HeLa Human Cervical Cancer Cells.A prospective study on neoadjuvant chemoradiotherapy plus anti-EGFR monoclonal antibody followed by surgery for locally advanced cervical cancer.Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
P2860
Q26824536-5BE9676E-1370-433A-995D-F59934FFEDB1Q30248499-5404CD17-F6A5-41FE-9954-4A8A094649C0Q33653218-0C9A81EE-370F-4BAF-81D5-7F645A1A778AQ34060669-1F81F397-7045-422D-805B-51730BA4EEBFQ34117589-818DC968-26C6-43D9-8C00-8A393FC3C5C5Q34494513-FCBDFED6-98B6-4431-B813-6E17929BA37EQ34677991-3519A70C-2741-426B-AEF2-F9AB1B462A50Q34809355-0455FF7A-6A7B-434C-AC2A-63623D74E107Q34979703-DADABBBD-D800-4673-8CA9-5C08A0D3DF0BQ35041529-ECCC474F-7F46-466C-80EF-EB943864CE82Q35112737-1C719BED-931A-4427-A361-A3D77AF8FE4BQ35548337-20E3C895-4ADA-489E-A228-37996318EF60Q35607137-8C389CB6-711D-4C45-8944-F3B12603BA90Q35788969-469706E2-5C18-48D9-A772-F57A3977DFA7Q36199783-78AF7A9F-EBB5-4C7B-A135-F47307081A7DQ36477507-7E04395D-34F0-4B38-A327-CD6FAD54AAC0Q36492850-2CFAB575-2718-41A1-A8AF-4AC06979007FQ36962526-7C25453C-C77B-4FFA-B33A-AE47C7A63E0BQ36977684-A1E511B6-29DD-43FF-BCC4-54F3FF0842F6Q37286023-42EC6C05-1E54-4544-91CD-A6473E0A76C9Q37445712-9EF5F66D-B73E-4A29-B5EA-B77797C96F63Q37618803-BD051D08-1F38-4350-A9E0-EFA2856C14A9Q38070655-B597D61B-96EE-46EE-AED8-1EC3AC5C840EQ38172182-D6D75166-1406-4FAE-96B0-E07F8FC2E565Q38216860-94381CD7-8684-4A4E-BF62-CB4F90511C5FQ38678038-A7F00E9C-1C69-4E67-A9CD-788A12ABA69DQ38761176-BE7FD41D-FC0C-4206-A0A6-57BA18F9CE04Q39093873-B7FCD1E9-988A-43D6-9C6B-55A3534236B9Q39297048-524FB7DA-5DD1-4FE2-BA1F-727EAD35629DQ42559322-51F3E546-1BAD-4513-BFDA-8FF3F5A679A5Q42732448-16885881-E9F0-4D8C-9008-DE86B58C3ED0Q44943966-C14FCFA9-7C66-42E5-922A-256F71857D79Q46380421-6EF57AEA-68C0-43DB-A54F-2E0B88963112Q49979672-FCAA0E45-C243-4619-BB82-93C47383F1A2Q54584675-F50556BD-035C-4DDB-B864-C9917DC972F2Q55426472-C7FA9825-AE38-471F-96AE-FCAD9985C897Q55717412-89B27623-BDB7-4707-8FDC-35678A94ED81Q57069094-0DB608FE-81AA-48C1-8581-2960B0A255F1
P2860
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Therapeutic targeting of epide ...... er: successes and limitations.
@ast
Therapeutic targeting of epide ...... er: successes and limitations.
@en
type
label
Therapeutic targeting of epide ...... er: successes and limitations.
@ast
Therapeutic targeting of epide ...... er: successes and limitations.
@en
prefLabel
Therapeutic targeting of epide ...... er: successes and limitations.
@ast
Therapeutic targeting of epide ...... er: successes and limitations.
@en
P2860
P921
P356
P1476
Therapeutic targeting of epide ...... er: successes and limitations.
@en
P2093
Jill Wykosky
Webster K Cavenee
P2860
P356
10.5732/CJC.010.10542
P5008
P577
2011-01-01T00:00:00Z